Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. News
Greenwich LifeSciences, Inc. Quantitative Score
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Greenwich LifeSciences, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Greenwich LifeSciences, Inc. Financials
Table Compare
Compare GLSI metrics with: | |||
|---|---|---|---|
Earnings & Growth | GLSI | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GLSI | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GLSI | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GLSI | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Greenwich LifeSciences, Inc. Income
Greenwich LifeSciences, Inc. Balance Sheet
Greenwich LifeSciences, Inc. Cash Flow
Greenwich LifeSciences, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Greenwich LifeSciences, Inc. Executives
| Name | Role |
|---|---|
| Snehal S. Patel | Chief Executive Officer, Chief Financial Officer & Director |
| Eric Rothe | Founder & Independent Director |
| Christine T. Fischette | VP of Business Development |
| Frank Joseph Daugherty | Chief Medical Officer & Director |
| Jaye L. Thompson | Vice President Clinical & Regulatory Affairs |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Snehal S. Patel | Chief Executive Officer, Chief Financial Officer & Director | Male | 1964 | 918.84K |
| Eric Rothe | Founder & Independent Director | Male | 1975 | 65.64K |
| Christine T. Fischette | VP of Business Development | 1951 | -- | |
| Frank Joseph Daugherty | Chief Medical Officer & Director | 1950 | -- | |
| Jaye L. Thompson | Vice President Clinical & Regulatory Affairs | 1966 | -- |
Greenwich LifeSciences, Inc. Insider Trades
| Date | 25 Nov |
| Name | Patel Snehal |
| Role | CEO and CFO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 4600 |
| Date | 13 Nov |
| Name | Patel Snehal |
| Role | CEO and CFO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 100000 |
| Date | 7 Nov |
| Name | Patel Snehal |
| Role | CEO and CFO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 10600 |
| Date | 31 Oct |
| Name | Patel Snehal |
| Role | CEO and CFO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 2300 |
| Date | 25 Apr |
| Name | Patel Snehal |
| Role | CEO and CFO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 3600 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 25 Nov | Patel Snehal | CEO and CFO | Acquired | P-Purchase | 4600 |
| 13 Nov | Patel Snehal | CEO and CFO | Acquired | A-Award | 100000 |
| 7 Nov | Patel Snehal | CEO and CFO | Acquired | P-Purchase | 10600 |
| 31 Oct | Patel Snehal | CEO and CFO | Acquired | P-Purchase | 2300 |
| 25 Apr | Patel Snehal | CEO and CFO | Acquired | P-Purchase | 3600 |